Sol-Gel Technologies (SLGL) Shares Outstanding (Weighted Average) (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Shares Outstanding (Weighted Average) of $2.8 million for Q1 2026, up 1.84% year-over-year from $2.8 million in Q1 2025, and up 1.83% quarter-over-quarter from $2.8 million in Q4 2025.
Sol-Gel Technologies (SLGL) Shares Outstanding (Weighted Average) (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $2.8 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $2.8 million, up 1.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 1.84% YoY), and the FY2025 annual result was $2.8 million, changed 0.0% from the prior year.
- Shares Outstanding (Weighted Average) advanced to $2.8 million in Q1 2026 per SLGL's latest filing, from $2.8 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $27.9 million in Q1 2024 and troughed at $2.3 million in Q4 2022.
- A 5-year average of $13.6 million and a median of $2.8 million in 2026 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) rose 19.59% in 2023, then tumbled 90.0% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $2.3 million in 2022, then rose by 17.11% to $2.7 million in 2023, then increased by 2.85% to $2.8 million in 2024, then gained by 0.0% to $2.8 million in 2025, then grew by 1.83% to $2.8 million in 2026.
- Business Quant data shows SLGL's Shares Outstanding (Weighted Average) at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 27.86 Mn |
| Mar 31, 2024 | 27.86 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 27.84 Mn |
| Jun 30, 2023 | 27.66 Mn |
| Mar 31, 2023 | 24.94 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Jun 30, 2022 | 23.13 Mn |
| Mar 31, 2022 | 23.13 Mn |
| Dec 31, 2021 | 23.06 Mn |
| Jun 30, 2021 | 23.03 Mn |
| Mar 31, 2021 | 23.00 Mn |
| Dec 31, 2020 | 22.57 Mn |
| Sep 30, 2020 | 23.00 Mn |